Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Dario Buononato; Gaetano Licata; Alessio Gambardella; Alina De Rosa; Giulia Calabrese; Giuseppe Argenziano

doi:10.5826/dpc.1202a49

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Authors

Dario Buononato Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Gaetano Licata Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Alessio Gambardella Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Alina De Rosa Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Giulia Calabrese Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Giuseppe Argenziano Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy

Keywords:

tildrakizumab, psoriatic arthritis, psoriasis, psoriasis treatment

References

1. Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019 Sep; 206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6. PMID: 30196070; PMCID: PMC6401348.
2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.

Downloads

Published

2022-05-02

Issue

2022 Vol 12, No 2 | April

Section

Research Letter

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Buononato D, Licata G, Gambardella A, De Rosa A, Calabrese G, Argenziano G. Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis. Dermatol Pract Concept. 2022;12(2):e2022049. doi:10.5826/dpc.1202a49